January 25, 2019, HemOnc Today 

Premenopausal women treated with letrozole as neoadjuvant endocrine therapy for HER2-negative breast cancer attained faster and more sustained ovarian function suppression with degarelix than with triptorelin, according to results of a randomized phase 2 trial published in Journal of Clinical Oncology. 

Read more.